
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists are effective at lowering blood sugar because they stimulate the pancreas to produce more insulin and slow the liver’s release of glucose. They are commonly introduced as a second line therapy when oral medications such as metformin no longer keep blood sugar within the recommended range. Certain GLP-1 agents have also been shown to provide heart protection by reducing the risk of cardiovascular events in patients with type 2 diabetes and pre existing heart disease.
For adults who do not have diabetes, GLP-1 agonists like Wegovy and Saxenda are FDA approved options for medical weight loss. These therapies increase the feeling of fullness and decrease appetite, helping patients eat less while still feeling satisfied. Evidence from clinical trials shows that when GLP-1 therapy is combined with lifestyle adjustments, many individuals experience significant long term weight reduction.
GLP-1 receptor agonists improve glycemic control by stimulating insulin release after meals and dialing back glucagon production. This dual action helps prevent large surges in blood glucose and keeps levels more stable throughout the day. Because they respond to how high glucose is, they are far less likely to trigger hypoglycemia than many commonly used diabetes drugs.
GLP-1 therapy is especially valued for its capacity to assist with long term weight reduction and weight maintenance. By slowing the emptying of the stomach and sending clear fullness signals to the brain, GLP-1 medications help lower appetite and make it easier for individuals to maintain a lower calorie intake over time. Clinical data confirm that agents like liraglutide, semaglutide, and tirzepatide can result in significant and persistent weight loss when paired with diet and lifestyle changes.



GLP-1/GIP co-agonists are designed to activate both GLP-1 and GIP receptors, creating a synergistic effect that increases insulin production and refines appetite control more effectively than targeting GLP-1 alone. This dual mechanism can lead to better management of blood glucose and reduced calorie intake, making these therapies a powerful option for people with diabetes and excess weight.
GLP-1/glucagon co-agonists engage receptors for GLP-1 and glucagon to promote weight loss and enhance overall energy metabolism, while helping to preserve lean muscle mass during treatment.

